PGMI-004A

CAS No. 1313738-90-7

PGMI-004A( —— )

Catalog No. M23473 CAS No. 1313738-90-7

PGMI-004A is an effective inhibitor of phosphoglycerate mutase 1 (IC50: 13.1 μM).

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 312 In Stock
50MG 1224 In Stock
100MG 1971 In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    PGMI-004A
  • Note
    Research use only, not for human use.
  • Brief Description
    PGMI-004A is an effective inhibitor of phosphoglycerate mutase 1 (IC50: 13.1 μM).
  • Description
    PGMI-004A is an effective inhibitor of phosphoglycerate mutase 1 (IC50: 13.1 μM).
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Metabolic Enzyme/Protease
  • Target
    Phospholipase
  • Recptor
    phosphoglycerate mutase 1?(PGAM1)
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    1313738-90-7
  • Formula Weight
    463.38
  • Molecular Formula
    C21H12F3NO6S
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO:125 mg/mL (269.76 mM)
  • SMILES
    C1=CC=C2C(=C1)C(=O)C3=CC(=C(C(=C3C2=O)O)O)S(=O)(=O)NC4=CC=C(C=C4)C(F)(F)F
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Hitosugi T, et al. Phosphoglycerate mutase 1 coordinates glycolysis and biosynthesis to promote tumor growth. Cancer Cell. 2012 Nov 13;22(5):585-600.
molnova catalog
related products
  • PF 5212372

    PF 5212372 (PLA-950, ZPL-521, ZPL 5212372) is a potent, selective inhibitor of cPLA2 (cytosolic phospholipase A2α) with IC50 of 7 nM.

  • LEI110

    LEI110 is a potent Phospholipase A2, group XVI (PLA2G16) inhibitor with an Ki value of 20 nM. LEI110 is a selective pan-inhibitor of the HRASLS family of thiol hydrolases (i.e., PLA2G16, HRASLS2, RARRES3 and iNAT).

  • IACS-13909

    IACS-13909, a specific and potent allosteric inhibitor of SHP2, that suppresses signaling through the MAPK pathway.